MCI Onehealth Technologies Inc. ("MCI") (TSX:
DRDR), a clinician-led healthcare technology company focused on
increasing access to and quality of healthcare, has appointed
Saleema Khimji as Chief Innovation Officer.
“Saleema’s appointment is the latest achievement
in MCI’s aggressive track record of tangible innovation. Since the
launch of MCI’s IPO in January 2021, Saleema has worked with MCI to
define and shape its innovation strategy and help build the MCI
ecosystem. I am thrilled that she has agreed to come onboard as our
Chief Innovation Officer and to be part of our leadership team,”
said Dr. Alexander Dobranowski, MD and CEO of
MCI.
To date, MCI has acquired or partnered with:
North America’s most advanced rare and specialty disease clinical
intelligence platform; a Canadian-leading personalized and
regenerative health provider with a genetics laboratory and
executive health service; a leading edge genomic data and stem cell
technology company who’s services are now available in MCI’s
clinics; and a precision medicine company that is transforming
genetic and clinical data into new insights for diagnosis and
advanced therapeutics. Additionally, MCI has created novel service
offerings for its more than 400 corporate clients; pioneered
virtual connection to patients’ doctors through MCI Connect, MCI’s
online patient experience platform; and, most recently, qualified
for a federal innovation grant to fund initiatives in artificial
intelligence (“AI”).
“MCI Onehealth exists to provide better patient
outcomes through applied innovation – in processes, care pathways,
health technology, clinical discoveries and in the mindset of the
integrated care team that includes the patient at its center. With
the seasoned and purpose-driven champion of innovation that we have
in Saleema, disciplined, creative, meaningful innovation across all
MCI business units and external collaborations will be amplified.
Saleema’s proven expertise and experience in leading large-scale,
complex and innovative projects around the globe will bring MCI to
the forefront of cutting-edge innovation within the industry and
undoubtedly influence the MCI Onehealth brand in the market,
helping draw diverse, creative talent and partners to support our
mission,” said Dobranowski.
Khimji brings a multidisciplinary range of
skills, experience, and education to the MCI table, having studied
at Dalhousie University, University of Windsor, University of
Warwick and Cambridge University with a global career spanning
multiple continents and disciplines. She has learned first-hand
that the best innovations come from the cross-pollination of
information and insights from diverse industries and people. Her
ability to understand synergies across various cultures, verticals
and geographies has made her a thought leader in the innovation
space, allowing her to nurture and create unique partnerships and
platforms for collaboration with ease. Khimji has
"walked the walk" when it comes to patenting and nurturing
technologies through the development life cycle, including as a
co-inventor of sensor technology for counterfeit drug detection
with the University of Oxford.
With her deep experience working with academic
institutions and governments at all levels across the globe in
advancing science and technology initiatives, her background in
fundraising and partnerships in both the public and private
sectors, as well as her legal background and IP expertise, Khimji
will continue to build and expand MCI’s relationships with centers
of academic and research excellence and will lead MCI’s research
and development initiatives under the MCI Onehealth Labs umbrella.
MCI Onehealth Labs is a business unit tasked with building a
reliable and long-term pipeline of intellectual property and
contributions to the growing body of clinical evidence that
benefits MCI patients, advances medical research and can improve
health systems in Canada and around the world. In direct support to
MCI’s CEO, Khimji will help accelerate clinical, research and
business opportunities with MCI’s current partners and
subsidiaries, as well as pharmaceutical, medical device and life
sciences companies, and medical technologies backed by AI.
“With the recent acceleration of digital and
technological advancements in the healthcare sector overall, it is
a critical time to ensure that innovation is translated in the
right way so that it drives the development and delivery of
quality, value-based care with tangible results for patients.
Central to this “innovation translation” are the primary care
doctors working on the ground, in the community, delivering care to
their patients every day. MCI is building an ecosystem to
enable just that: to strategically enhance its ecosystem of health
services with a focus on putting patient-centered care and improved
patient outcomes at the forefront, and to bring cutting-edge
research developments and technologies into the clinic to directly
impact patients at the primary point of care. Clinician-led
innovation and research will not only be essential in shaping the
future of healthcare delivery, but will be critical in generating
real-world evidence and actionable insights that meaningfully
contribute to the advancement of precision medicine. I’m honored
and thrilled to be leading the charge in innovation for MCI and
look forward to bringing my experience to the leadership team and
the entire MCI ecosystem,” said Khimji.
While providing access to high-quality,
accountable care to nearly one million patients each year, MCI
continues to identify, prioritize, develop, and launch new
products, services and business models that create positive health
impact and investor value. Khimji’s appointment enables MCI to
accelerate execution on its comprehensive precision health and
technology roadmap, while supporting its long-term vision of
building a data-driven, technology-enabled health services
platform.
About MCI:
MCI is a healthcare technology company focused
on empowering patients and doctors with advanced technologies to
increase access, improve quality, and reduce healthcare costs. As
part of the healthcare community for over 30 years, MCI operates
one of Canada’s leading primary care networks with 25 clinics,
serves over 850,000 patients annually and had over 200,000
telehealth visits last year. MCI additionally offers an expanding
suite of occupational health service offerings that support a
growing list of over 400 corporate customers. Led by a proven
management team of doctors and experienced executives, MCI remains
focused on executing a strategy centered around acquiring
technology and health services that complement the company’s
current roadmap.
For more information, visit
mcionehealth.com.
For IR enquiries please
contact:Fernando Massalin | ir@mcionehealth.com | +1 (416)
440-4040 ext 155
For media enquiries please
contact:Nolan Reeds | nolan@mcionehealth.com | +1 (416)
440-4040 ext 158
Forward-Looking Statements This
press release contains forward-looking information and
forward-looking statements (together, “forward-looking statements”)
within the meaning of applicable securities legislation, which
reflect MCI’s current expectations regarding future events,
including statements relating to: the relationship between MCI and
its business and strategic partners (including the expected
benefits thereof), the impact of MCI’s new Chief Innovation Officer
on MCI’s service offerings, technology roadmap, relationships with
strategic partners and long-term strategic plan, and MCI’s
continuing efforts to launch new products, services and business
models. In some cases, but not necessarily in all cases,
forward-looking statements can be identified by the use of words or
phrases such as “create”, “continue to”, “expand”, “accelerate”,
“enhancing”, or variations of such words and phrases or state that
certain actions, events or results “may”, “could”, “would”, “might”
or “will” occur. Forward-looking statements are based on a number
of assumptions and are subject to a number of risks and
uncertainties, many of which are beyond MCI’s control, which could
cause actual results and events to differ materially from those
that are disclosed in or implied by such forward-looking
statements. Such risks and uncertainties include difficulties
forming or breakdowns in MCI’s relationships with existing or
potential future business partners; changes in MCI’s senior
management and employees; difficulties or delays in the development
of new technologies, products or services; technologies, products
and services not functioning as expected; third parties not using
technologies, products or services as expected; economic conditions
making technologies, products and services less attractive than
anticipated; competitors in the industry; and other factors
discussed under “Risk Factors” in the Company’s annual information
form for the year ended December 31, 2020 which is available under
the Company’s profile on SEDAR at www.sedar.com. All
forward-looking statements made in this press release are made as
of the date hereof and MCI does not undertake any obligation to
update such forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
MCI Onehealth Technologies (TSX:DRDR)
Historical Stock Chart
From Sep 2024 to Oct 2024
MCI Onehealth Technologies (TSX:DRDR)
Historical Stock Chart
From Oct 2023 to Oct 2024